top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Aug 22, 2023
What is the purpose of registration submission guide, based on data from scientific literature?
Feb 9, 2021
Publication of the Public Consultation for the review of RDC 200 - what is new?
Feb 9, 2021
NEW REGULATORY FRAMEWORK OF API
Feb 9, 2021
COVID-19: What facilities is ANVISA providing at this time of crisis?
Feb 9, 2021
Why are 24% of drug registrations still rejected?
Feb 9, 2021
API, BPF and drug dossier - How to align the processes to ensure success in registration?
Feb 9, 2021
NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
Feb 9, 2021
Publication of the new API regulatory framework: what is essential to know?
Feb 9, 2021
Outcome of the RDC 200 Review Working Group meeting - 02/05/20
Feb 9, 2021
Cannabis: the rules of the new regulation system.
Feb 9, 2021
Everything you need to know about the new rules for Drug Renewal.
Feb 9, 2021
API: Why control it?
Feb 9, 2021
CTD - Why?
Feb 9, 2021
Which points generate the most rejections and demands in innovative drug processes?
Feb 9, 2021
DDCM- What are the most demanding requirements by ANVISA?
Feb 9, 2021
Practical aspects of biosimilar registration
Feb 9, 2021
Comparability of biosimilars: unraveling this enigma
Feb 9, 2021
ANVISA’S new era: is the regulatory sector prepared for this?
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
